Last reviewed · How we verify
NCT05699044: ATTRAB
Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation
trial testing Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy) in Amyloid Cardiomyopathy in 170 participants. Status unknown.
1 August 2025
Quick facts
| Lead sponsor | Steen Hvitfeldt Poulsen |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 170 |
| Start date | 1 October 2022 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 October 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)
Conditions studied
- Amyloid Cardiomyopathy — all drugs for Amyloid Cardiomyopathy →
- Block, AV — all drugs for Block, AV →
Sponsor
Steen Hvitfeldt Poulsen — full company profile →
Who can join
65 and older, any sex, with Amyloid Cardiomyopathy or Block, AV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05699044
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyloid Cardiomyopathy
Currently open trials in the same condition.
- NCT07382128 — Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes · recruiting
- NCT06634108 — Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy · Phase 1, PHASE2 · recruiting
- NCT05797857 — Exercise Training in Transthyretin Cardiac Amyloidosis · NA · recruiting
- NCT05103943 — Amyloidosis TTR Flow Reserve Evaluation · NA · active not recruiting
- NCT04776824 — Swiss Cardiac Amyloidosis REgistry (Swiss-CARE) · recruiting
Other Steen Hvitfeldt Poulsen trials
Trials by the same sponsor.
- NCT06372301 — Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy · NA · recruiting
- NCT05701410 — Prevalence of Cardiac Amyloidosis Among Patients With a History of Lumbar Spinal Stenosis. · NA · unknown
- NCT05701397 — Prevalence of Cardiac Amyloidosis in Patients Undergoing Surgery for Lumbar Spinal Stenosis. · NA · unknown
- NCT05633563 — The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Dia · Phase 4 · completed
- NCT04276220 — Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05699044 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Steen Hvitfeldt Poulsen
- Last refreshed: 2 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699044.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing